SNM extends trials network to Europe

Jul 22, 2009

Nuclear medicine society SNM of Reston, VA, announced that its Clinical Trials Network has expanded its membership with several European commercial providers of PET radiopharmaceuticals.

Advanced Accelerator Applications of Saint Genis Pouilly, France; Erigal Limited of South London and Dublin; and IBA Molecular, a division of Belgian radiopharmaceutical firm Ion Beam Application (IBA), have all joined the network, SNM said. The three companies represent 27 PET manufacturing sites in Europe.

The SNM Clinical Trials Network has received investigational new drug (IND) status for the use of fluorothymidine in multicenter studies. The goal of the network is to receive multicenter IND status for additional imaging biomarkers over time. Advanced Accelerator Applications, Erigal Limited, and IBA Molecular have all expressed interest in participating in future multicenter clinical trials under SNM INDs, according to SNM.

There are currently 201 manufacturing sites registered with the network worldwide, with 23% located in European regions, SNM said.

Society of Nuclear Medicine issues Medical Isotope Communiqué, June 16, 2009

Moly crisis overshadows SNM Image of the Year award, June 15, 2009

SNM poll: Isotope shortage affecting users, procedures, June 15, 2009

Canadian health minister meets SNM execs, June 15, 2009

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$